Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma
Authors
Keywords
-
Journal
CANCER
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-06-28
DOI
10.1002/cncr.32339
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer
- (2018) Chenlu Zhang et al. BMC CANCER
- Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma
- (2018) Valerie Chew et al. GUT
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine
- (2018) Karin M. Knudson et al. OncoImmunology
- Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
- (2018) Rikke B. Holmgaard et al. Journal for ImmunoTherapy of Cancer
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer
- (2018) SHINKICHI TAKAMORI et al. ANTICANCER RESEARCH
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells
- (2017) Rachel M. Gibbons Johnson et al. Frontiers in Immunology
- PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis
- (2016) Omar Abdel-Rahman Immunotherapy
- Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030
- (2016) Jessica L. Petrick et al. JOURNAL OF CLINICAL ONCOLOGY
- Pseudoprogression and Immune-Related Response in Solid Tumors
- (2015) Victoria L. Chiou et al. JOURNAL OF CLINICAL ONCOLOGY
- Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis
- (2015) Laëtitia Basset et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Roles for Chemokines in Liver Disease
- (2014) Fabio Marra et al. GASTROENTEROLOGY
- Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer
- (2013) M. Sznol et al. CLINICAL CANCER RESEARCH
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Interferon γ-induced intratumoral expression of CXCL9 alters the local distribution of T cells following immunotherapy withListeria monocytogenes
- (2013) Patrick Guirnalda et al. OncoImmunology
- Radiofrequency Thermal Ablation for Hepatocellular Carcinoma Stimulates Autologous NK-Cell Response
- (2010) Alessandro Zerbini et al. GASTROENTEROLOGY
- T-cell exhaustion: characteristics, causes and conversion
- (2010) John S. Yi et al. IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search